Antifibrotic medication is increasingly complex. Add-on treatments are in clinical trials, or available, for patients progressing on first-line idiopathic pulmonary fibrosis or progressive fibrosis interstitial lung disease therapy. This Breathe Journal Club looks at the BI 101550 and RELIEF trials, placing them within current clinical practice.
Read the article in full | Submit to Breathe
Friday, 6 October 2023
Breathe: pick of the week
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment